Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MANNKIND CORPMNKD · Entity 4792 | Pres, Endocrine Business Unit | July 15, 2026 | July 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MANNKIND CORP
Report date July 15, 2026 · Filed July 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 Par ValueSEC Table I · non-derivative | Direct | 343,398 |
Reported balance
After 2026-07-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-15 · Tax withholding · Disposed 3,623 · Balance 343,398 F1: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. F2: Includes 2,775 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.
F2: Includes 2,775 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2026 Filed Jul 18, 2026 01:47 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 3,623 | $4.09 | $14,818.07 |
DisclosureSEC source: 0001193125-26-308137 · ownership.xml · nonDerivative · entry 1 Marasco Dominic · CIK 0002053897 · Pres, Endocrine Business Unit 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 343,398 F1 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. F2 · balance_after: Includes 2,775 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2026. Read SEC document |
| May 20, 2026 Filed May 23, 2026 00:48 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $0.01 Par Value | 8,474 | $2.95 | $24,998.30 |
DisclosureSEC source: 0001193125-26-237428 · ownership.xml · nonDerivative · entry 1 Marasco Dominic · CIK 0002053897 · Pres, Endocrine Business Unit 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 344,246 F1 · kind: The securities were purchased through the Issuer's Market Price Stock Purchase Plan effective May 29, 2018. The purchase was approved by the Company's Board of Directors on May 20, 2026. F2 · balance_after: Includes 2,343 shares acquired under the Issuer's Employee Stock Purchase Plan on December 31, 2025. Read SEC document |
| June 23, 2025 Filed Jun 26, 2025 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantPerformance Restricted Stock Unit · Derivative | 1,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-090116 · ownership.xml · derivative · entry 1 Marasco Dominic · CIK 0002053897 · Pres, Endocrine Business Unit 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock, $0.01 Par Value · 1,000,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · derivative.exercise_date: The performance-based restricted stock unit will vest on March 15, 2028. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, will be determined by the achievement of a specified net sales target, with the potential payout ranging from 0% to 200%. F2 · derivative.expiration_date: The performance-based restricted stock unit will vest on March 15, 2028. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, will be determined by the achievement of a specified net sales target, with the potential payout ranging from 0% to 200%. Read SEC document |
| May 14, 2025 Filed May 16, 2025 22:20 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantPerformance Restricted Stock Unit · Derivative | 72,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-073800 · ownership.xml · derivative · entry 3 Marasco Dominic · CIK 0002053897 · Pres, Endocrine Business Unit 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,500 Underlying: Common Stock, $0.01 Par Value · 72,500 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F4 · derivative.exercise_date: The performance-based restricted stock unit will vest on July 15, 2028. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2025 until June 30, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F4 · derivative.expiration_date: The performance-based restricted stock unit will vest on July 15, 2028. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2025 until June 30, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| May 14, 2025 Filed May 16, 2025 22:20 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $0.01 Par Value | 21,929 | $4.56 | $99,996.24 |
DisclosureSEC source: 0000950170-25-073800 · ownership.xml · nonDerivative · entry 2 Marasco Dominic · CIK 0002053897 · Pres, Endocrine Business Unit 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 333,429 F2 · kind: The securities were purchased through the Issuer's Market Price Stock Purchase Plan effective May 13, 2023. The purchase was approved by the Company's Board of Directors on May 14, 2025. Read SEC document |
| May 14, 2025 Filed May 16, 2025 22:20 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $0.01 Par Value | 59,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-073800 · ownership.xml · nonDerivative · entry 1 Marasco Dominic · CIK 0002053897 · Pres, Endocrine Business Unit 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 311,500 F1 · kind: Acquired pursuant to a Restricted Stock Unit Award: 25% vest on July 15, 2026 and each yearly anniversary thereof until fully vested. Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 02:30 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $0.01 Par Value | 252,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-020295 · ownership.xml · nonDerivative · entry 1 Marasco Dominic · CIK 0002053897 · Pres, Endocrine Business Unit 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 252,000 F1 · kind: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · kind: Four-year vesting schedule with no shares vesting on the first anniversary of the vesting determination date of January 6, 2025 and one-third on each anniversary thereafter until fully vested on the fourth anniversary of the vesting determination date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.